Which of the following will be the most limiting factor for manufacturers to use the FDA’s guidance documents in the development of “complex generic drugs"? (poll 9863742)

Which of the following will be the most limiting factor for manufacturers to use the FDA’s guidance documents in the development of “complex generic drugs"?

Limited time and resources of the FDA

High cost of developing complex generic drugs

Low return on investment

Complex clinical testing to prove equivalence

None of these

Vote View Results

See this poll on: https://poll.fm/9863742/embed